Stifel Reiterates Buy on Iovance Biotherapeutics, Maintains $25 Price Target
Benzinga · 09/15 12:57
Stifel analyst Benjamin Burnett reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $25 price target.